Previous reviews have shown that ß-blocker use for the treatment of hypertension without compelling indications was associated with increased risk of stroke in the elderly. It remains unclear whether this increased risk was driven by the type of ß-blocker. We sought to compare the efficacy of atenolol vs nonatenolol ß-blockers in clinical trials enrolling young (